MET and lung carcinoma: Since MET amplification is a common resistance mechanism to different TKI resistances in lung cancer and inhibitors are available to be used, it is then critical to detect MET amplification with appropriate methods and cut-offs so that patients can be identified to be offered potential anti-MET treatment.